Anti-complement component C5 mAb synergizes with CTLA4Ig to inhibit alloreactive T cells and prolong cardiac allograft survival in mice

American Journal of Transplantation

Volumn 11, Issue 7, 2011, Pages 1397-1406

  Raedler, H ^a   Vieyra, M B ^a   Leisman, S ^a   Lakhani, P ^a   Kwan, W ^a   Yang, M ^a   Johnson, K ^b   Faas, S J ^b   Tamburini, P ^b   Heeger, P S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ALEXION PHARMACEUTICALS   (United States)

Author keywords

C5; Complement; CTLA4Ig; T cell; transplant rejection

Indexed keywords

ABATACEPT; ANTIGEN; CHEMOATTRACTANT; CHEMOKINE; COMPLEMENT COMPONENT C5 INHIBITOR; GAMMA INTERFERON; MONOCLONAL ANTIBODY;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DONOR; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; IN VIVO STUDY; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECIPIENT; T LYMPHOCYTE; TH17 CELL; TH2 CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; COMPLEMENT C5; DRUG SYNERGISM; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOCONJUGATES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TRANSPLANTATION, HOMOLOGOUS;

EID: 79959844134     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03561.x     Document Type: Article

References (46)

1. Lamb KE, Lodhi S, Meier-Kriesche HU,. Long-term renal allograft survival in the United States: A critical reappraisal. Am J Transplant 2011; 11: 450-462.
2. Bromberg JS, Heeger PS, Li XC,. Evolving paradigms that determine the fate of an allograft. Am J Transplant 2010; 10: 1143-1148.
3. Valujskikh A, Baldwin WM, 3rd, Fairchild RL,. Recent progress and new perspectives in studying T cell responses to allografts. Am J Transplant 2010; 10: 1117-1125.
4. Goldstein DR,. Inflammation and transplantation tolerance. Semin Immunopathol 2011. doi
5. Schenk AD, Rosenblum JM, Fairchild RL,. Chemokine-directed strategies to attenuate allograft rejection. Clin Lab Med 2008; 28: 441-454, vii.
6. Ricklin D, Hajishengallis G, Yang K, Lambris JD,. Complement: A key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785-797.
7. Baldwin WM, Ota H, Rodriguez ER,. Complement in transplant rejection: Diagnostic and mechanistic considerations. Springer Semin Immunopathol 2003; 25: 181-197. (Pubitemid 37130013)
8. Wehner J, Morrell CN, Reynolds T, Rodriguez ER, Baldwin WM, 3rd,. Antibody and complement in transplant vasculopathy. Circ Res 2007; 100: 191-203. (Pubitemid 46208719)
9. Qian Z, Wasowska BA, Behrens E, et al,. C6 produced by macrophages contributes to cardiac allograft rejection. Am J Pathol 1999; 155: 1293-1302. (Pubitemid 29488936)
10. Collins AB, Schneeberger EE, Pascual MA, et al,. Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208-2214. (Pubitemid 29453499)
11. Rother RP, Arp J, Jiang J, et al,. C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients. Am J Transplant 2008; 8: 1129-1142.
12. Wang H, Arp J, Liu W, et al,. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol 2007; 179: 4451-4463.
13. Wang H, Jiang J, Liu W, et al,. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine. Transplantation 2005; 79: 1121-1127. (Pubitemid 40664008)
14. Stegall M, Tayyab D, Lynn C, et al,. Terminal Complement Inhibition Decreases Early Acute Humoral Rejection in Sensitized Renal Transplant Recipients. Am J Transplant 2010; 10: s4:39.
15. Sheerin NS, Risley P, Abe K, et al,. Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury. FASEB J 2008; 22: 1065-1072. (Pubitemid 351519961)
16. Tang Z, Lu B, Hatch E, Sacks SH, Sheerin NS,. C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol 2009; 20: 593-603.
17. Raedler H, Yang M, Lalli PN, Medof ME, Heeger PS,. Primed CD8(+) T cell responses to allogeneic endothelial cells are controlled by local complement activation. Am J Transplant 2009; 9: 1784-1795.
18. Pavlov V, Raedler H, Yuan S, et al,. Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection. J Immunol 2008; 181: 4580-4589.
19. Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS,. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T cell expansion by limiting antigen-induced apoptosis. Blood 2008; 112: 1759-1766.
20. Liu J, Lin F, Strainic MG, et al,. IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production. J Immunol 2008; 180: 5882-5889.
21. Strainic MG, Liu J, Huang D, et al,. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008; 28: 425-435.
22. Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS,. Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production. J Immunol 2007; 179: 5793-5802.
23. Heeger PS, Lalli PN, Lin F, et al,. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005; 201: 1523-1530. (Pubitemid 40720998)
24. Peng Q, Li K, Sacks SH, Zhou W,. The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses. Inflamm Allergy Drug Targets 2009; 8: 236-246.
25. Li K, Anderson KJ, Peng Q, et al,. Cyclic AMP plays a critical role in C3a-receptor-mediated regulation of dendritic cells in antigen uptake and T cell stimulation. Blood 2008; 112: 5084-5094.
26. Peng Q, Li K, Anderson K, et al,. Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction. Blood 2008; 111: 2452-2461. (Pubitemid 351451459)
27. Peng Q, Li K, Patel H, Sacks SH, Zhou W,. Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol 2006; 176: 3330-3341. (Pubitemid 43363979)
28. Frei Y, Lambris JD, Stockinger B,. Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies. Mol Cell Probes 1987; 1: 141-149.
29. Valujskikh A, Lantz O, Celli S, Matzinger P, Heeger PS,. Cross-primed CD8(+) T cells mediate graft rejection via a distinct effector pathway. Nat Immunol 2002; 3: 844-851.
30. Valujskikh A, Pantenburg B, Heeger PS,. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant 2002; 2: 501-509. (Pubitemid 36306868)
31. Raedler H, Yang M, Lalli PN, Medof ME, Heeger PS,. Primed CD8 T cell responses to allogeneic endothelial cells are controlled by local complement activation. Am J Transplant 2009; 9: 1784-1795.
32. Benichou G, Valujskikh A, Heeger PS,. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol 1999; 162: 352-358. (Pubitemid 29018940)
33. Chen Y, Heeger PS, Valujskikh A,. In vivo helper functions of alloreactive memory CD4+ T cells remain intact despite donor-specific transfusion and anti-CD40 ligand therapy. J Immunol 2004; 172: 5456-5466. (Pubitemid 38542046)
34. Chen Y, Demir Y, Valujskikh A, Heeger PS,. Antigen location contributes to the pathological features of a transplanted heart graft. Am J Pathol 2004; 164: 1407-1415. (Pubitemid 38387806)
35. Asgari E, Zhou W, Sacks S,. Complement in organ transplantation. Curr Opin Organ Transplant 2010; 15: 486-491.
36. Patel H, Smith RA, Sacks SH, Zhou W,. Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol 2006; 17: 1102-1111.
37. Farrar CA, Zhou W, Lin T, Sacks SH,. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J 2006; 20: 217-226. (Pubitemid 44933168)
38. Gloor J, Stegall MD,. Sensitized renal transplant recipients: Current protocols and future directions. Nat Rev Nephrol 2010; 6: 297-306.
39. Lonze BE, Singer AL, Montgomery RA,. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010; 362: 1744-1745.
40. Li Q, Peng Q, Xing G, et al., Deficiency of C5aR prolongs renal allograft survival. J Am Soc Nephrol 2010; 21: 1344-1353.
41. Banda NK, Thurman JM, Kraus D, et al,. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J Immunol 2006; 177: 1904-1912. (Pubitemid 44092530)
42. Thurman JM, Lenderink AM, Royer PA, et al,. C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion. J Immunol 2007; 178: 1819-1828. (Pubitemid 46154654)
43. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM,. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol 2003; 170: 1517-1523. (Pubitemid 36139523)
44. De Vries B, Matthijsen RA, Wolfs TG, Van Bijnen AA, Heeringa P, Buurman WA,. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: Inhibition of late apoptosis and inflammation. Transplantation 2003; 75: 375-382. (Pubitemid 36222966)
45. Ferraresso M, Macor P, Valente M, et al,. Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement. Transplantation 2008; 86: 1445-1451.
46. Vincenti F, Larsen C, Durrbach A, et al,. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781. (Pubitemid 41215486)